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ABSTRACT 
Objective:Influenza is a highly transmitted disease and about 10% of the world’s population is 
affected by  this disease annually. The aim of this research was to study the variation of serum 
antibody levels among subjects who had already been vaccinated against influenza. 
Methods And Materials:This descriptive-analytical study was carried out on 196 subjects who 
had influenza vaccination (influvac 2005/2006) and on 200 subjects who were matched with the 
vaccinated subjects by their ages in Gorgan which is located in the northeast of Iran. The 
subject's sera were prepared seven weeks after the influenza vaccination. Their serum antibody 
levels were determinated by the heamaglutination inhibition test. 
Results:The antibody titre in 81 subjects of the vaccinated group and in 175 subjects of the 
control group was less then 1/40. The mean antibody titre of the vaccinated subjects and the 
control group was 143.4±10.89 and 18.34±3.2, respectively. The difference was statistically 
significant  (P value=0.000). 
Conclusion:The findings showed that the mean titre of the antibodies in the vaccinated and 
control groups was statistically different. This means that the influenza vaccine has good 
efficacy in our population. 
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Introduction 
Influenza is a highly transmitted disease and about
10% of the world’s population is affected by this
disease annually. Influenza is the sixth reason of
death in the world and the forth reason of death in
old people. 
The virus is continuously undergoing antigenic
changes and thus, it can bypass the host's acquired
immunity to influenza [1]. 
The virus causing the disease is transmitted easily
by coughing and sneezing, from person to person
and spreads very fast in the society. Infection by
the influenza virus without signs and symptoms
may cause severe diseases or even death.
Almost 30 to 50 percent of the people infected by
the virus do not have special signs and symptoms,
but they can transmit the disease to others. The
best way of prevention is vaccination.
Elderly individuals not only demonstrate a greater
risk of morbidity and mortality due to influenza
than the young, but also have a greater difficulty
in mounting a protective response to the influenza
vaccine [2]. 
The Disease Control Center of America reports
that vaccination of people prevents them from
getting the disease (70 to 90% of the cases in
people under 60 years and 30 to 40% of the cases
in people above 60 years old). According to a
study in America, in all the 88 subjects who were
vaccinated against influenza by the
Haemaglutination inhibition test ( HI ), an
increase in antibody levels was observed [3]. 
Increase in antibody titre was observed in 5000
subjects from different ages who were vaccinated
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against influenza in Poland using the
Haemaglotination inhibition test ( HI ) [4]. 
In a study in France, 21 out of 285 subjects who
were vaccinated against influenza showed
changes in the levels of antibody serum [5]. 
In England, changes in the levels of antibody
serum were observed in only 18.2% of the 137
subjects who were vaccinated and they were
above 82 years old [6]. In an observed study in
Turkey in which the subjects were vaccinated
against influenza, an increase in the antibody titre
in the vaccinated group was observed [7]. In a
study in Norway, 19 subjects were vaccinated
against influenza and an increase in the levels of
antibody serum was observed in all the subjects
[8]. This study was designed in order to
investigate the changes in the levels of antibody
serum in the vaccinated subjects as compared to
the unvaccinated ones and to specify the ratio of
the increase in the antibody titre up to the level of
prevention. 
Materials and Methods 
In this descriptive analytical research, 196
subjects were vaccinated against influenza by the
vaccine "influ vac 2005/2006" which is made in
Netherlands.The vaccine included 45 micrograms
of Haemaglotination and Noraminidaz proteins
and was extracted from the following viruses.
After 7 weeks, they took transfusions of 5
milititres and their serum were collected and
preserved under 20 ˚C until the experiment was
carried out. 
The Vaccine Virus Included
1-A/California/7/2/2004(H3N2)-Like strain
(A/New York/55/2004 NYMC X-157) 
2-A/New Caledonia/20/99 (H1N1)-Like strain
(A/New Caledonia/20/99 IVR-116) 
3-B/Shanghai/361/2002-Like strain
(B/Jiangsu/10/2003)
200 subjects who were as old as the vaccinated
subjects were selected from blood donor samples
and the serum was prepared. At the time of getting
the sample, 196 subjects filled out the information
collection from which demographic information
was obtained. All of the vaccinated subjects and
the control group were tested by the
Haemaglutintion inhibition test to determine the
anti-influenza antibody levels, by methods which
were previously described [9],[10]. A titre above
40 units of agglutination was considered by the
preventive antibody Haemaglotination inhibition
test [11].
The data of the antibody titration in serum and the
demographic information was entered into the
computer and the mean of the antibody titre of the
studied groups (vaccinated and unvaccinated
subjects) was compared with appropriate
statistical tests such as the T-test. The Chi-Square
test was used to investigate the relationship
between groups of different ages, genders and the
existence of the preventive antibody in the
subjects. 
Results 
In this study, 396 subjects were included. In the
case group, the male to female ratio was 0.9 and
in the control group it was 0.8. The mean age of
the vaccinated group was 52.2 ± 11 years and in
the control group it was 48.6 ± 5.1 years. 
Preventive levels of antibodies against influenza
was found in 115 (58.7%) out of the 196
vaccinated subjects and in the control group, it
was found in 15 subjests (7.5%). 
Immunity levels against the influenza virus in the
vaccinated subjects and controls according to the
age groups is shown in [Table/Fig 1].
The mean antibody titre in the vaccinated and
control groups were compared by the T-test,
which showed a significant difference
them(CI=95% :102.91-144.22; P value=0.000)
[Table/Fig 2]. 
The comparison between the mean antibody titre
�
between the two genders in the vaccinated group
�
didn't show a significant difference by the T-test.
�
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Discussion 
In this study, it was shown that the vaccine was
efficient in the vaccinated group and moreover,
the existence of these levels of the preventive
antibody in 7.5% of the control group showed the
circulation of the vaccine viruses among the
Gorgan population; especially in one percent of
these people, an antibody titre above 512 units of
Haemaglutination was found.
A study in America showed that vaccination of
subjects under 65 years is preventive in 70 to 90%
of the cases and doesn't have any similarities to
the results of our study, but for people above 65
years, the preventive level was found to be
between 30 to 45% [5].
In our study , the preventive level was about
58.1% in the subjects between 60-80 years. A
study in Turkey showed that in vaccinated
subjects, the increase in the anti-influenza
antibody titre was significant as compared to the
control group and is similar to the results of our
study [5]. 
The result of a study in Norway has shown an
increase in the anti-influenza antibody titre in all
vaccinated subjects [8].
In our study, this level included 58.7% of the
vaccinated subjects, for which the reason might be
the environmental and background factors
involved in the vaccinated subjects. Another study
has also reported antibody levels of 72%, which
doesn't have any similarities to our study [12].
A study carried out in France reported a changing
level of antibody titre in the vaccinated subjects to
7.4% [13].
A study carried out in Iran on 32370 Hajis, out of
which 3465 of them were vaccinated with the
influenza vaccine, prevented them from getting
influenza like diseases in 52% of the cases as
compared to the unvaccinated group [14].
This is similar to the results of our study. But
these results depend on the conditions of choosing
the samples, techniques for searching for the
antibodies and underlying factors of the
vaccinated subjects, environmental factors and
especially, different age ranges of the subjects
under investigation. 
The mean antibody titre in the vaccinated subjects
was 143.4 with an SE equal to 10.86 and in the
control group, it was 18.34 with an SE equal to
3.2, that were statistically significantly different
and these are similar to the results of the study
which was carried out in Turkey [7].
One of the limitations of the research was the lack
of measurement of the levels of the antibody titre
against each specific injected vaccine viruses. 
Finally, according to the results of the study, it is
recommended that in the regions or countries
where influenza is epidemic, vaccination against
the influenza virus must be done, which is
preventive in more than 50% of these subjects and
prevent them from severe influenza and the side
effects resulting from it. 
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